Olcegepant - Novel Therapy for Acute Migraine
Key Data:
Drug (brand/generic)
Olcegepant (BIBN 4096)
Company/licensee
Boehringer Ingelheim Pharmaceuticals
Therapy class
Selective Calcitonin Gene-Related Peptide (CGRP) antagonist
Product description
Inhibits the release and action of Calcitonin Gene-Related Peptide (CGRP)
Current indication
Acute migraine
Market sector
CNS, analgesics
Development status
Phase II
